Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (29393)	11/15/1999 7:12:00 PM
From: Mudcat	Read Replies (2) \| Respond to of 32384

Bob, Panretin results were really disappointing. They are still selling from the original inventory. Loss about 25% worse than analysts were predicting. Cost of products and services were almost as much as the revenues for those products. Selling, general and administrative expenses were up. The $2.2 million increase is attributable to expansion of sales and marketing activities for ONTAK and Panretin gel. We obviously didn't get much in return for these activities. Overall not a great report in my opinion, maybe you can tell me why the stock is up a half in after hour trading?